HUP0301465A3 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents

Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Info

Publication number
HUP0301465A3
HUP0301465A3 HU0301465A HUP0301465A HUP0301465A3 HU P0301465 A3 HUP0301465 A3 HU P0301465A3 HU 0301465 A HU0301465 A HU 0301465A HU P0301465 A HUP0301465 A HU P0301465A HU P0301465 A3 HUP0301465 A3 HU P0301465A3
Authority
HU
Hungary
Prior art keywords
composition
dosage forms
therapeutic agents
controlled release
forms including
Prior art date
Application number
HU0301465A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HUP0301465A2 publication Critical patent/HUP0301465A2/hu
Publication of HUP0301465A3 publication Critical patent/HUP0301465A3/hu

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
HU0301465A 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition HUP0301465A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04
PCT/US2001/020134 WO2002000213A1 (fr) 2000-06-23 2001-06-22 Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition

Publications (2)

Publication Number Publication Date
HUP0301465A2 HUP0301465A2 (hu) 2004-05-28
HUP0301465A3 true HUP0301465A3 (en) 2006-07-28

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301465A HUP0301465A3 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Country Status (11)

Country Link
EP (1) EP1305021A4 (fr)
JP (1) JP2004501190A (fr)
KR (1) KR20030013460A (fr)
AU (2) AU6872201A (fr)
CA (1) CA2412490A1 (fr)
CZ (1) CZ2003199A3 (fr)
EA (1) EA200300046A1 (fr)
HU (1) HUP0301465A3 (fr)
IL (1) IL153497A0 (fr)
MX (1) MXPA02012793A (fr)
WO (1) WO2002000213A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
JP2005501097A (ja) * 2001-08-16 2005-01-13 ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー 膨張可能な胃内滞留装置
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
EP1615632B1 (fr) * 2003-04-17 2006-12-06 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
JP2007509146A (ja) * 2003-10-20 2007-04-12 テバ ファーマシューティカル インダストリーズ リミティド レボドーパの持続効果のための組成物及び投与形
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006050581A2 (fr) 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
EP2242489A1 (fr) 2005-02-15 2010-10-27 Jallal Messadek Compositions therapeutiques combinees et leurs procedes d utilisation
RU2007143510A (ru) 2005-04-27 2009-06-10 Яллал МЕССАДЕК (BE) Инсулиновые композиции
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
EP1872775A1 (fr) * 2006-06-29 2008-01-02 Polichem S.A. Emploi d'une matrice hydrophile contenant un dérivé polyacrylique, un éther de cellulose et un désintégrant, pour la production d'un médicament pour le traitement des troubles génitales d'une femme
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
WO2008039186A2 (fr) * 2006-09-26 2008-04-03 Plensat, Llc Méthode et système de traitement de troubles de l'alimentation
JPWO2008087882A1 (ja) 2007-01-15 2010-05-06 キッセイ薬品工業株式会社 胃内滞留型レボドパ徐放性製剤
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
DE102007026037A1 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
EP2306823A4 (fr) 2008-06-30 2012-09-26 Tocagen Inc Formulations de 5-fluorocytosine et leurs utilisations
ES2740360T3 (es) * 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
JP2012508228A (ja) * 2008-11-07 2012-04-05 サムヤン コーポレイション メチルフェニデートの放出制御用薬剤学的組成物
EP2661262B1 (fr) * 2011-01-06 2017-11-15 Mahmut Bilgic Formulations améliorées de bisphosphonates
CN103385871B (zh) * 2012-05-07 2017-06-23 新疆医科大学 复方左旋多巴微囊漂浮片
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
WO2014174388A1 (fr) * 2013-03-29 2014-10-30 Wockhardt Limited Compositions pharmaceutiques à libération modifiée de méthylphénidate ou de ses sels
JP6204141B2 (ja) * 2013-04-22 2017-09-27 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
WO2014176389A1 (fr) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Forme pharmaceutique solide contenant de l'arabinogalactane
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
WO2015083171A1 (fr) * 2013-12-05 2015-06-11 Tulip Medical Ltd. Dispositifs et systèmes de rétention pour la libération in-situ d'agents pharmaceutiques actifs
EP3261625B1 (fr) * 2015-02-27 2024-08-14 Cingulate Therapeutics LLC Formulations de stimulant de libération à trois impulsions
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
WO2018232413A1 (fr) 2017-06-16 2018-12-20 Kashiv Pharma Llc Formes posologiques à rétention gastrique destinées à une administration de médicament prolongée
DK3609472T3 (da) 2018-06-18 2021-04-06 Kashiv Specialty Pharmaceuticals Llc Forlænget frigivelsessammensætning indeholdende pyridostigmin
JP7034343B2 (ja) 2018-06-27 2022-03-11 アムニール コンプレックス プロダクツ リサーチ エルエルシー 自己調節性の浸透性胃保持性薬物送達システム
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
EP3968980A1 (fr) * 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Traitement de symptômes nocturnes et de l'akinésie matinale chez des sujets atteints de la maladie de parkinson
WO2020264092A1 (fr) * 2019-06-26 2020-12-30 Celista Pharmaceuticals Llc Compositions de chlorhydrate d'atomoxétine à libération prolongée et procédés d'utilisation
WO2021176361A1 (fr) 2020-03-02 2021-09-10 Craft Health Pte Ltd Procédé de fabrication de formes posologiques orales pour libération prolongée de médicament
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (fr) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques
GB202414411D0 (en) * 2024-10-01 2024-11-13 King S College London Hydrogel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
JP2001510788A (ja) * 1997-07-23 2001-08-07 ペリオ プロダクツ リミテッド 薬学的薬剤を薬学的に口腔内に制御放出するためのタンニン酸ポリマー組成物

Also Published As

Publication number Publication date
MXPA02012793A (es) 2004-07-30
AU6872201A (en) 2002-01-08
CZ2003199A3 (cs) 2003-12-17
IL153497A0 (en) 2003-07-06
AU2001268722B8 (en) 2005-09-29
HUP0301465A2 (hu) 2004-05-28
CA2412490A1 (fr) 2002-01-03
JP2004501190A (ja) 2004-01-15
EA200300046A1 (ru) 2003-10-30
EP1305021A1 (fr) 2003-05-02
EP1305021A4 (fr) 2009-09-23
KR20030013460A (ko) 2003-02-14
AU2001268722B2 (en) 2005-08-11
WO2002000213A1 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
IL154521A0 (en) Contraception process and administration form for the same
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
MXPA03003895A (es) Formulaciones de hidrocodona de liberacion controlada.
HUP0301242A3 (en) Controlled release drug dosage form
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB0002386D0 (en) Therapeutic composition
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
AU2001232948A1 (en) Controlled release of drugs
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures
GB0030067D0 (en) Therapeutic agent
IL155819A0 (en) Methods of treatment comprising administration of substance p
MXPA03000856A (es) Agente terapeutico cristalino.
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
AU2001272552A1 (en) Oxygen-enriched agent and the use thereof for therapeutic purposes

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees